People and Places

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Dr. Richard Schilsky, Dr. Edward Pan, Pam Kedziera

Dr. Richard Schilsky

Richard L. Schilsky, MD, associate dean for clinical research at the University of Chicago Pritzker School of Medicine, has been elected president of the American Society of Clinical Oncology for the 2008-2009 term. He will be inducted as president-elect at ASCO's 43rd Annual Meeting in June 2007. Dr. Schilsky's interests include GI cancers, cancer pharmacology, and drug development.

Dr. Edward Pan

The Orlando campus of M.D. Anderson has added neuro-oncologist Edward Pan, MD, to its staff. Dr. Pan comes to M.D. Anderson from the Florida Hospital Cancer Institute where he was co-medical director of neuro-oncology. Prior to that appointment, he was on faculty as a clinical instructor for the Brain Tumor Research Center at the University of California, San Francisco.

Pam Kedziera

Fox Chase Cancer Center has named Pam Kedziera, RN, MSN, ACON, as clinical director of the center's pain and palliative care program. In her new role, she will help lead expansion of the pain management center into a broader focused program while continuing to direct the staff and programs offered at the center. Ms. Kedziera has been affiliated with Fox Chase since 1980.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content